- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02680288
Lorcaserin Intra Venous Cocaine Effects (LIVE)
Lorcaserin Effects on Cocaine Craving and Drug-Reinforced Behavior
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background
Serotonin (5-HT) is one of three brain monoamines that are widely distributed in the brain and play important roles in affect and goal-directed behaviors. Limbic structures that underlie behavior motivated by palatable food and drugs of abuse receive dense projections from brainstem serotonergic nuclei. In rats, light and sound cues associated with access to cocaine strongly stimulate drug-seeking behavior. Agonists for the type 2C serotonergic receptor (5-HT₂cR) attenuate this responding.8 Drug taking (cocaine self-administration) is also attenuated at 5-HT₂cR agonist doses similar to those that decrease food-reinforced responding and cause reductions in locomotor activity.
Lorcaserin is a novel and selective agonist of the 5-HT₂cR recently approved by the FDA for weight loss therapy. It acts selectively at this receptor subtype with minimal activation of 5-HT₂ᴀR or 5-HT₂ᴃR receptors. Based on initial clinical studies leading to its approval, lorcaserin is well tolerated and probably does not cause cardiac valve disease or other serious side effects. Even so, given the potential for serious adverse events, the FDA has limited its use to patients who are either obese or overweight with a medical complication such as hypertension. Whether or not lorcaserin will become generally accepted as a long-term treatment for obesity will depend on the results of ongoing post-marketing studies of cardiovascular outcome data.
Rationale In preclinical studies, agonists for the 5-HT₂cR potently attenuate cocaine-seeking behavior. Lorcaserin is a recently approved selective 5-HT₂cR agonist with an acceptable safety profile in humans. No published studies have reported its effects on cocaine-induced craving or drug-reinforced responding in humans.
Specific Aims:
- Evaluate whether lorcaserin treatment attenuates the positive subjective effects of cocaine and drug-reinforced behavior.
- Determine whether active treatment modifies cocaine- or script- induced craving.
Methods This is a randomized, cross-over, double-blind, placebo-controlled, single-center, multiple-panel evaluation of the potential for oral lorcaserin to modify cocaine self-administration in a laboratory setting. Up to 32 non-treatment-seeking, regular cocaine users will receive treatment with single doses of oral placebo, lorcaserin 10 mg (Panel 1), or lorcaserin 20 mg (Panel 2). Script-guided imagery of autobiographical memories will be developed based on experiences related to cocaine use, anger, and a neutral event. Following treatment with lorcaserin, script-induced emotional states will be assayed. Sampling doses of cocaine (0.0, 0.23, and 0.46 mg/kg) will be administered, and participants will choose between self-administering additional intravenous doses or receiving monetary alternatives. Detailed measures of the negative and positive subjective effects of intravenous infusions will also be made. As noncontingent infusions of cocaine are administered, the pharmacokinetics of cocaine and lorcaserin will be determined.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Midwest Biomedical Research Foundation KCVA
- Phone Number: (816) 499-1614
- Email: Kenneth.Grasing@va.gov
Study Locations
-
-
Missouri
-
Kansas City, Missouri, United States, 64128
- Recruiting
- Kansas City VA Medical Center
-
Contact:
- Kenneth W Grasing, M.D.
- Phone Number: 816-922-2756
- Email: kenneth.grasing@va.gov
-
Principal Investigator:
- Kenneth W Grasing, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Is non-treatment-seeking and has used cocaine regularly for at least six months.
- Has used cocaine by a rapid route of administration (smoked or intravenous injection), at least three times per week, for three of the preceding six weeks.
- Is male or female, between 21 and 50 years old.
- Is able to verbalize understanding of the consent form, able to provide written informed consent, and verbalize willingness to complete study procedures.
- Is agreeable to the study schedule and likely to complete all interventions and measures.
- Has a medical history, physical exam, and screening laboratory results that demonstrate no contraindication to participation.
Exclusion Criteria:
- Has a history of a medical adverse reaction to cocaine or other psycho stimulants, including loss of consciousness, chest pain, cardiac ischemia, or seizure.
- Has any current Axis I psychiatric disorder other than drug abuse or dependence.
- Meets DSM-IV-TR criteria for dependence on opiates, benzodiazepines, alcohol, or other sedative-hypnotics.
- Has received opiate-substitution therapy within two months prior to enrollment.
- Has a current or past history of seizure disorder other than febrile seizures, including alcohol- or psycho stimulant- related seizures, or family history of seizure disorder.
- Has a diagnosis of adult asthma or chronic obstructive pulmonary disease.
- Has had head trauma that resulted in neurological sequelae (e.g., loss of memory for greater than 5 minutes).
- Has a history of valvular heart disease, congestive heart failure, syncope, bradycardia, or any other cardiac condition.
- Has a condition that increases the risk of cocaine-induced hypertension or ischemic heart disease, such as hypertension, hypercholesterolemia, renal disease (serum creatinine > 1.4 mg/dl), diabetes (fasting glucose level ≥ 100 mg/dl).
- Has a history of jaundice, hepatitis, or laboratory evidence of hepatic insufficiency (total bilirubin ≥ 2.0, serum albumin ≤ 3.5 gm./dl); or current abnormalities of liver function testing with serologic evidence of hepatitis (serology and coagulation will be evaluated in individuals with aspartate transaminase or Alaine aminotransferase > 40 IU/L).
- History of priapism or conditions that would predispose to priapism (sickle cell anemia, multiple myeloma, leukemia, Peyronie's disease, or other anatomical deformation of the penis).
- Currently being treated for erectile dysfunction.
- Has an unstable medical condition, which, in the judgment of investigators, would make participation hazardous, such as AIDS or active TB.
- If female, is pregnant or lactating (nursing), not practicing adequate methods of contraception, or planning to become pregnant within one month of conclusion of the study.
- Has current suicidal ideation as assessed by the SCID interview.
- Has clinically significant ECG abnormalities, including QTc interval prolongation > 450 milliseconds in men or 480 milliseconds in women.
- Has donated blood or participated in another clinical trial within 4 weeks of enrollment.
- In the opinion of investigators, is expected to fail to complete the study protocol due to probable incarceration or relocation from the clinic area.
- Has had known or suspected hypersensitivity to Lorcaserin.
- Is currently being treated with an adrenergic receptor antagonist ('beta blocker').
- Is currently receiving Lorcaserin, potential CYP2D substrates, or medications associated with the serotonin syndrome or neuroleptic-malignant syndrome (see Tables 8 and 9).
- Has a significant potential for violent behavior, as assessed by the Structured Assessment of Violence Risk in Youth (SAVRY).23
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Oral Placebo
Oral inert treatment
|
Oral inert treatment
|
Experimental: Active Treatment, Low-Dose
Lorcaserin 10 mg, single dose
|
Oral type 2C serotonergic agonist, low-dose
Other Names:
|
Experimental: Active Treatment, High-Dose
Lorcaserin 20 mg, single dose
|
Oral type 2C serotonergic agonist, high-dose
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cocaine-Induced 'High'
Time Frame: Day 1 of Lorcaserin Treatment
|
Visual analogue scale rating of 'high' after receiving cocaine
|
Day 1 of Lorcaserin Treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cocaine-Induced Craving
Time Frame: Day 1 of Lorcaserin treatment.
|
Visual analogue scale rating of 'How much do you WANT to use cocaine' after receiving intravenous cocaine
|
Day 1 of Lorcaserin treatment.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Kenneth W Grasing, MD, Midwest Biomedical Research Foundation
Publications and helpful links
General Publications
- Burmeister JJ, Lungren EM, Kirschner KF, Neisewander JL. Differential roles of 5-HT receptor subtypes in cue and cocaine reinstatement of cocaine-seeking behavior in rats. Neuropsychopharmacology. 2004 Apr;29(4):660-8. doi: 10.1038/sj.npp.1300346.
- Cunningham KA, Fox RG, Anastasio NC, Bubar MJ, Stutz SJ, Moeller FG, Gilbertson SR, Rosenzweig-Lipson S. Selective serotonin 5-HT(2C) receptor activation suppresses the reinforcing efficacy of cocaine and sucrose but differentially affects the incentive-salience value of cocaine- vs. sucrose-associated cues. Neuropharmacology. 2011 Sep;61(3):513-23. doi: 10.1016/j.neuropharm.2011.04.034. Epub 2011 May 11.
- Pirtle JL, Hickman MD, Boinpelly VC, Surineni K, Thakur HK, Grasing KW. The serotonin-2C agonist Lorcaserin delays intravenous choice and modifies the subjective and cardiovascular effects of cocaine: A randomized, controlled human laboratory study. Pharmacol Biochem Behav. 2019 May;180:52-59. doi: 10.1016/j.pbb.2019.02.010. Epub 2019 Feb 24.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- MIRB#0016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cocaine Use Disorders
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA); Columbia UniversityNot yet recruitingCocaine Use Disorder | Cocaine Dependence | Cocaine Use | Cocaine Use Disorder, Moderate | Cocaine Use Disorder, Severe
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)Active, not recruitingMethamphetamine Use Disorder | Cocaine Use Disorder | Cocaine Dependence | Methamphetamine Dependence | Stimulant Use Disorder | Methamphetamine Abuse | Cocaine Abuse | Stimulant Abuse | Stimulant UseUnited States
-
Midwest Biomedical Research FoundationNational Institute on Drug Abuse (NIDA)CompletedCocaine Use DisordersUnited States
-
New York State Psychiatric InstituteCompletedCocaine Use DisordersUnited States
-
National Institute on Drug Abuse (NIDA)The University of Texas Health Science Center, HoustonCompleted
-
William StoopsNational Institute on Drug Abuse (NIDA)CompletedCocaine Use DisordersUnited States
-
Friends Research Institute, Inc.National Institute on Drug Abuse (NIDA)RecruitingOpioid Use Disorder | Opioid Use | Cocaine Use Disorder | Cocaine UseUnited States
-
University of Maryland, BaltimoreNational Institute on Drug Abuse (NIDA)Withdrawn
-
University of Maryland, BaltimoreNational Institute on Drug Abuse (NIDA)Completed
-
National Institute on Drug Abuse (NIDA)Withdrawn
Clinical Trials on Oral Placebo
-
VA Office of Research and DevelopmentActive, not recruitingSuicidal IdeationUnited States
-
Evelo Biosciences, Inc.CompletedPsoriasis | Atopic DermatitisUnited Kingdom
-
Sao Thai Duong Joint Stock CompanyBig Leap Clinical Research Joint Stock CompanyCompleted
-
Eidos Therapeutics, a BridgeBio companyWithdrawnTransthyretin-Related (ATTR) Familial Amyloid PolyneuropathyUnited States
-
Royan InstituteUnknownInfertilityIran, Islamic Republic of
-
Pulmagen TherapeuticsCompleted
-
Georgetown UniversityNational Institutes of Health (NIH)RecruitingDementia With Lewy BodiesUnited States
-
University of British ColumbiaCrohn's and Colitis CanadaWithdrawnInflammatory Bowel Diseases | Ulcerative ColitisCanada
-
Applied Molecular TransportActive, not recruitingUlcerative ColitisUnited States, Hungary, Ukraine, Germany, United Kingdom, Belarus, Bulgaria, Canada, France, Georgia, Moldova, Republic of, Poland, Russian Federation, Switzerland
-
WockhardtCompleted